

Contents

- 1. Welcome
- 2. Key points of the last EC meeting
- 3. Contact

Issue n°25 – June 2023

Dear SIOPEN members,

We are happy to provide you with the 24th SIOPEN Flash news. Key points:

- Update on high-risk neuroblastoma protocols
- SIOPEN pharmacists
- SIOPEN structure review
- Extension of funding for the Bioportal Manager post
- SIOPEN AGM meeting details
- SIOPEN EUSA supported webinar

Best wishes, Maja Beck Popovic, SIOPEN President



Contents

- 1. Welcome
- 2. Key points of the last EC meeting
- 3. Contact

HR-NBL2 update

- The Trial Steering Committee have agreed that protocol version 2.0 will be amended and version 3.0 will include:
 - Irinotecan and temozolomide chemotherapy and dinutuximab-beta x 4 courses for patients having an inadequate response to induction chemotherapy.
 - Lorlatinib plans to incorporate lorlatinib treatment for patients with Alk over expression and mutation into version 3.0 need further discussion and consideration with Pharma.
 - CTIS (Clinical Trial Information System) from January 2025 all EU countries will need to migrate to the new protocol version simultaneously, which will be challenging to coordinate.

SIOPEN Pharmacists

- Tiene Bauters and Mapi Fleury gave an overview of SIOPEN pharmacist activities to the EC&AB.
 Future plans include:
 - Pharmacists are keen to collaborate and develop networks to support and educate colleagues across SIOPEN countries and plan webinars, e-learning tools.
 - Early involvement in protocol design and writing.
 - Any pharmacists wishing to be involved in SIOPEN pharmacy group are welcome to contact Mapi Fleury Mapi.Fleury@chuv.ch or Tiene Bauters tiene.bauters@uzgent.be



Contents

- 1. Welcome
- 2. Key points of the last EC meeting
- 3. Contact

SIOPEN structure - review

- Current SIOPEN structure of EC&AB, Board and Specialty Committee has remained unchanged for past 25 years and EC&AB agree that the structures need to be modified to address the current challenges detailed in the SIOPEN strategy review.
- Proposed changes include changing membership of the EC&AB, frequent SIOPEN board meetings to enhance engagement with national deputies and a new annual scientific meeting in January.
- The proposed changes will be considered further and plan to be presented at the AGM 2023 for validation.

SIOPEN Bioportal Manager – extension of funding

- Current funding is until August 2023 and an application for 3 year extension of funding has been submitted. The application detailed the major impact of the post in supporting the activities of SIOPEN.
- EC&AB have reviewed the application and agreed funding for a further 3 years and will consider the role being a core SIOPEN post in the future.



Contents

- 1. Welcome
- 2. Key points of the last EC meeting
- 3. Contact

SIOPEN AGM 2023

- 4-6 October 2023, Ljubljana, Slovenia.
- Provisional programme and registration link: <u>siopen-ljubljana.si</u>

SIOPEN – EUSA supported webinar

- 19.9.23 17:00 19:00 (CET)
- More details to be circulated







Contents

- 1. Welcome
- 2. Key points of the last EC meeting
- 3. Contact

Contacts



SIOPEN members website http://members.siopen.org/
SIOPEN public website https://www.siopen.net/



SIOPEN President

<u>maja.beck-popovic@chuv.ch</u>

Assistant of SIOPEN president

<u>elena.lemmel@chuv.ch</u>

SIOPEN Vice President ☑ <u>lucas.moreno@vhebron.net</u>
SIOPEN Vice President ☑ <u>cormac.owens@olchc.ie</u>